Inder Sehgal

TL;DR: The introduction of the gene for wild-type human p53 or p21 into a p53-deficient mouse prostate cancer cell line using a recombinant adenoviral vector suggests that Ad5CMV-p21 may be effective as a therapeutic agent for prostate cancer.

TL;DR: It is demonstrated that HSV-tk + GCV cytotoxic gene therapy can inhibit the growth of mouse and human prostate cancer cells in vitro and interrupt tumor growth of an aggressive mouse prostate cancer cell line in vivo.

TL;DR: MMP-9 expression is required for hematogenous metastasis in a murine prostate model system raising the possibility that it may play an equivalent role in human prostate cancer.

TL;DR: Comparisons of growth and extracellular matrix responses to TGF-β in six metastatic and six primary tumor-derived cell lines in a mouse model of prostate cancer suggest that acquisition of differential responses to the T GF-β family could results in phenotypic traits which facilitate tumor metastasis from certain primary site clones.

TL;DR: Limited anti-tumor and anti-metastatic activity is indicated in this highly aggressive in vivo mouse model of prostate cancer, yet 4-HPR treatment significantly suppressed the development of bone metastases revealing a novel and potentially clinically useful activity of this retinoid.